Researchers have discovered hepatitis C virus (HCV) in the brain lining of individuals with schizophrenia and bipolar ...

Observational studies of psychiatric diseases such as schizophrenia, bipolar disorder and major depression have long tied ...

A new medical study out of Johns Hopkins Children's Center could potentially be a game changer for those suffering certain ...

A new study published in Nature Mental Health has found that people with a higher genetic risk for schizophrenia tend to have ...

COBENFY works differently than the currently available schizophrenia medications. "Due to its heterogeneous nature, schizophrenia is not a one-size-fits-all condition, and people often find ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be answered about scalability and costs, experts say.

In a study of more than eight million U.S. older adults, about 28 percent of those with schizophrenia had dementia by age 66 compared to just over 1 percent without schizophrenia.

Cobenfy (xanomeline-trospium chloride) was approved for the treatment of adults with schizophrenia in 2024. Cobenfy is the first medicine approved for the treatment of schizophrenia that works ...

In this dose-finding study, adults aged 18 to 55 years with schizophrenia were randomized (2:1) to either NBI-1117568 (dose arms: 20 mg, 40 mg, 60 mg once daily; 30 mg twice daily) or placebo.

Schizophrenia is a relatively rare but disabling psychotic disorder that affects less than 1% of people around the world. But schizophrenia is more common among refugee and immigrant populations.

SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia ...